Published in Cancer Manag Res on January 07, 2010
Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines. J Transl Med (2015) 1.46
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat (2012) 0.84
Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions. World J Clin Oncol (2014) 0.82
Expression of eag1 channel associated with the aggressive clinicopathological features and subtype of breast cancer. Int J Clin Exp Pathol (2015) 0.75
Neurotoxicity of biologically targeted agents in pediatric cancer trials. Pediatr Neurol (2012) 0.75
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med (2006) 17.08
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 13.81
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol (2010) 4.94
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat (2008) 4.84
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol (2009) 4.69
The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther (2001) 4.37
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene (2002) 3.87
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol (2008) 3.83
HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A (2004) 3.43
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol (2008) 3.35
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev (2008) 3.13
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2008) 3.08
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol (2005) 2.77
Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol (2009) 2.71
Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst (2008) 2.24
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J Clin Oncol (2008) 1.93
Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol (2005) 1.92
Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther (2008) 1.90
Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol (2009) 1.89
Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene (2004) 1.89
Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res (2007) 1.88
Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat (2009) 1.86
Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol (2009) 1.79
A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol (2008) 1.66
Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer. J Clin Oncol (2008) 1.37
Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Clin Cancer Res (2008) 1.30
The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology (2003) 1.29
Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat (2008) 1.15
Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest New Drugs (2005) 1.05
Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res Treat (2008) 1.01
Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat (2009) 0.93
Can we circumvent resistance to ErbB2-targeted agents by targeting novel pathways? Clin Breast Cancer (2008) 0.91
Monitoring circulating epithelial tumour cells (CETC) to gauge therapy: in patients with disease progression after trastuzumab persisting CETC can be eliminated by combined lapatinib treatment. J Cancer Res Clin Oncol (2008) 0.83
How should we prescribe lapatinib to our patients: once daily or twice daily, and at what dose? J Clin Oncol (2008) 0.77
Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol (2012) 2.64
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst (2008) 1.95
Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat (2009) 1.86
HER2-positive circulating tumor cells in breast cancer. PLoS One (2011) 1.73
HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res (2008) 1.63
Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer. Clin Cancer Res (2010) 1.57
Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer (2011) 1.53
Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol (2011) 1.52
The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast Cancer Res Treat (2010) 1.50
Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst (2009) 1.47
Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer. Clin Breast Cancer (2004) 1.46
Management of triple negative breast cancer. Breast (2010) 1.43
Metabolomics: available results, current research projects in breast cancer, and future applications. J Clin Oncol (2007) 1.42
Equivalence between ovarian suppression and chemotherapy in the adjuvant treatment of endocrine-responsive breast cancer. J Clin Oncol (2002) 1.39
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol (2009) 1.34
Breast cancer assessment tools and optimizing adjuvant therapy. Nat Rev Clin Oncol (2010) 1.32
Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Res (2009) 1.28
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat (2012) 1.26
Targeting triple negative breast cancer: is p53 the answer? Cancer Treat Rev (2013) 1.23
Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther (2004) 1.17
Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer. J Clin Oncol (2003) 1.13
Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res (2005) 1.13
Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clin Breast Cancer (2002) 1.11
Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study. J Clin Oncol (2009) 1.07
Uncovering the metabolomic fingerprint of breast cancer. Int J Biochem Cell Biol (2010) 1.04
DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes. Oncologist (2013) 1.04
Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther (2006) 1.03
Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. Clin Cancer Res (2008) 1.02
HER2 discordance between primary and metastatic breast cancer: assessing the clinical impact. Cancer Treat Rev (2013) 1.00
HEX expression and localization in normal mammary gland and breast carcinoma. BMC Cancer (2006) 0.98
Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3-98. Psychooncology (2013) 0.97
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res Treat (2012) 0.96
Predicting anthracycline benefit: have we made any progress? Curr Opin Oncol (2009) 0.95
The nutritional risk in oncology: a study of 1,453 cancer outpatients. Support Care Cancer (2012) 0.95
Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). Eur J Cancer (2007) 0.94
Resistance to trastuzumab: a necessary evil or a temporary challenge? Clin Breast Cancer (2002) 0.92
Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study. Mol Oncol (2012) 0.92
Breast cancer in the elderly: which lessons have we learned? Future Oncol (2013) 0.90
Using specific cytotoxics with a targeted mind. Breast (2007) 0.90
Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime? Eur J Cancer (2008) 0.90
Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278). Clin Breast Cancer (2008) 0.89
Feasibility of evaluating quality cancer care using registry data and electronic health records: a population-based study. Int J Qual Health Care (2012) 0.88
Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy. Curr Opin Oncol (2014) 0.87
Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up? Ecancermedicalscience (2013) 0.86
Polyendocrine treatment in estrogen receptor-positive breast cancer: a "FACT" yet to be proven. J Clin Oncol (2012) 0.86
International study on inter-reader variability for circulating tumor cells in breast cancer. Breast Cancer Res (2014) 0.86
PTEN and Egr-1 expression in thyroid proliferative lesions. Cancer Lett (2004) 0.85
Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers. BMC Med (2015) 0.84
Markers of the uPA system and common prognostic factors in breast cancer. Am J Clin Pathol (2007) 0.83
The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients. Cancer Treat Rev (2009) 0.83
The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study. PLoS One (2013) 0.83
Chemotherapy for metastatic breast cancer. Curr Opin Obstet Gynecol (2004) 0.82
Triple negative breast cancer: a heterogeneous subgroup defined by what it is not. Eur J Cancer (2011) 0.82
Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology. Breast Cancer Res Treat (2013) 0.82
Extensive deep vein thrombosis as a complication of testicular cancer treated with the BEP protocol (bleomycin, etoposide and cisplatin): case report. Sao Paulo Med J (2006) 0.82
Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. Tumori (2012) 0.81
Gastric cancer metastatic to the pituitary gland: a case report. Tumori (2007) 0.81
The continued evidence from overviews: what is the clinical utility? Breast (2013) 0.81
Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients -- a jungle? Eur J Cancer (2007) 0.80
Adjuvant systemic treatment for individual patients with triple negative breast cancer. Breast (2011) 0.80
Anthracyclines: the first generation of cytotoxic targeted agents? A possible dream. J Clin Oncol (2008) 0.79
Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. Curr Med Res Opin (2010) 0.79
Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancer. Cancer Treat Rev (2002) 0.79
Adjuvant chemotherapy--the dark side of clinical trials. Have we learnt more? Breast (2009) 0.78
Significance of micrometastases: circulating tumor cells and disseminated tumor cells in early breast cancer. Cancers (Basel) (2010) 0.77
Adjuvant chemotherapy: which patient? What regimen? Am Soc Clin Oncol Educ Book (2013) 0.76
HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice. Anticancer Res (2002) 0.76
Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer. Future Oncol (2011) 0.76
Taxanes in the elderly: can we gain as much and be less toxic? Crit Rev Oncol Hematol (2008) 0.76
Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients. Breast (2012) 0.76
TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer. Future Oncol (2013) 0.75
Re-searching anthracycline therapy. Breast Cancer Res Treat (2010) 0.75
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin. J Clin Oncol (2002) 0.75
Ode to a past emperor. J Clin Oncol (2010) 0.75
Special focus on cardiac toxicity of different sequences of adjuvant doxorubicin/docetaxel/CMF regimens combined with radiotherapy in breast cancer patients. Radiother Oncol (2008) 0.75
3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study. Anticancer Res (2002) 0.75
[HER2 and topoisomerase II alpha: useful clinical markers in breast cancer]. Bull Cancer (2008) 0.75
Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: where do we stand? Crit Rev Oncol Hematol (2007) 0.75